Sara Mancini, PA

Sara Mancini practices at The Bryn Mawr Urology Group in Rosemont, Pennsylvania.

Sara Mancini's NPI, 1790972305, was assigned on September 27, 2007. Sara Mancini holds Pennsylvania license MA051133.

Sara Mancini's primary practice is The Bryn Mawr Urology Group, at 919 Conestoga Road, Rosemont, PA 19010. The practice phone is (610) 525-6580.

Sara Mancini's primary practice is The Bryn Mawr Urology Group in Rosemont, Pennsylvania. The medical group on file is Bryn Mawr Skin & Cancer Institute. Dmand AI also links Sara Mancini to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Sara Mancini practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Sara Mancini's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Sara Mancini is licensed in Pennsylvania.

CMS data shows 51 Medicare services from Sara Mancini across 4 procedure codes in 2024, for 32 Medicare patients. Medicare paid $2,929 for them. Every service was in an office.

CMS counts 32 Medicare patients who saw Sara Mancini in 2024. The largest group is 65 to 74, with 17 patients. 72% of them have high cholesterol, and 66% have high blood pressure. Their average risk score is 0.76, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Sara Mancini's median patient age at 48, with 77% women.

In 2024, Sara Mancini wrote 621 Medicare Part D claims for 320 patients. 90% of them were for generic drugs. CMS names the drug for 495 of them, across 14 drugs with 11 or more claims each, at $60,215 in total drug cost. In 2023, CMS named 409 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Sara Mancini for performance year 2024, reported as part of a group. Sara Mancini accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 522 general payments to Sara Mancini from 26 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 98% of the total. Abbvie Inc. paid the most, $1,443.